Page last updated: 2024-08-23

epirubicin and T-Cell Lymphoma

epirubicin has been researched along with T-Cell Lymphoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Chen, L; Chu, X; Liu, X; Wang, Y; Xu, L1
Baines, S; Elliott, J1
Choi, CW; Choi, IK; Choi, JG; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sul, HR; Sung, HJ1
Choi, CW; Jung, KY; Kim, BS; Kim, CY; Kim, IS; Kim, JS; Kim, SJ; Seo, HY; Seol, HR; Sung, HJ1
Bu, Q; Cai, QQ; Gao, Y; Guan, ZZ; Huang, HQ; Jiang, WQ; Lin, XB; Pan, ZH; Wang, BF; Xia, ZJ; Xu, RH1

Other Studies

5 other study(ies) available for epirubicin and T-Cell Lymphoma

ArticleYear
Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.
    Medicine, 2022, Mar-04, Volume: 101, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Glucocorticoids; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma, T-Cell; Male; Middle Aged; Positron-Emission Tomography; Rituximab; Treatment Outcome; Vincristine

2022
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
    Australian veterinary journal, 2019, Volume: 97, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dog Diseases; Dogs; Epirubicin; Female; Lomustine; Lymphoma, T-Cell; Male; Neutropenia; Prednisolone; Retrospective Studies; United Kingdom; Vincristine

2019
Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.
    British journal of haematology, 2006, Volume: 134, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Cells; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neutropenia; Prednisone; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine

2006
Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Killer Cells, Natural; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Vincristine

2006
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vincristine

2007